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Acute stroke is complicated by oropharyngeal dysphagia in 50% of patients; of these, up to 40% remain dysphagic a 
year later.1 Dysphagia is complicated by aspiration, pneumonia, 
and malnutrition,2 and patients need enteral feeding through 
a nasogastric tube or percutaneous endoscopically introduced 
gastrostomy tube, which often requires long-term institutional 
care.3 Although dysphagia may be treated using several physical 
and behavioral techniques, there are no definitive treatments.4
Human swallowing has bilateral representation in the 
cerebral hemispheres with a dominant cortex (unrelated to 
handedness).5 Dysphagia often follows a stroke that affects 
the dominant swallowing cortex, which is then exacerbated 
in recurrent strokes. Swallowing is dependent on afferent 
feedback via bulbar cranial nerves innervating the phar-
ynx, and increased sensory input from the pharynx can 
drive long-term beneficial changes in the cortical control of 
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swallowing6 with functionally relevant reorganization of the 
swallowing cortex.6,7
During development of pharyngeal electric stimulation 
(PES), a study in healthy volunteers8,9 suggested that PES 
should be delivered at 5 Hz for 10 minutes with an electric 
current of threshold plus 75% of the difference between 
threshold and tolerance levels, a paradigm that produced the 
largest effect on brain excitability.8,10 Using this approach in 
patients with subacute stroke in a randomized dose-compar-
ison trial, PES reduced radiological aspiration, manifest as a 
reduction in penetration aspiration score (PAS).9 Similarly, 
PES reduced clinical dysphagia (assessed using the dysphagia 
severity rating scale [DSRS]) and length of stay in hospital 
in patients with dysphagia post stroke in a sham-controlled 
parallel-group phase II trial.9 In a further multicentre phase II 
randomized sham-controlled trial, PES was associated with 
nonsignificant tendencies to reduced clinical dysphagia and 
shorter length of stay in hospital.11 An individual patient data 
meta-analysis of these 3 trials found that PES significantly 
reduced aspiration (PAS) and dysphagia (DSRS) and was safe 
and well tolerated.12 Here, we present the results of a large, 
randomized, sham-controlled phase III trial of PES in patients 
with subacute poststroke dysphagia.
Materials and Methods
Participants
We did an international, multicenter, randomized, sham-controlled, 
patient-masked, outcome assessor–masked, parallel-group trial, as 
detailed in the online-only Data Supplement. In brief, patients with a 
recent stroke and videofluoroscopy (VFS)-confirmed dysphagia were 
randomized to 3 days of PES or sham stimulation, and the primary 
outcome was the penetration aspiration scale, assessed using VFS, at 
2 weeks after the third treatment session.
Patients were eligible for the trial if they were admitted to hospital 
with a clinical stroke syndrome because of ischemic or hemorrhagic 
stroke, were aged ≥18 years, had clinical dysphagia identified using 
bedside testing (as assessed by a nurse or speech and language thera-
pist using a local clinical assessment and confirmed by failure on the 
Toronto Bedside Swallowing Screening Test), were alert or rousable 
(score of 0 or 1 on question 1a of the National Institutes of Health Stroke 
Scale [NIHSS]), had a PAS ≥3 (see the online-only Data Supplement for 
description) of for at least 1 swallow (assessed using VFS),13 and could 
be treated within 42 days of stroke onset. The diagnosis of ischemic or 
hemorrhagic stroke was confirmed with computed tomography or mag-
netic resonance imaging performed between hospitalization and enroll-
ment and using standard imaging techniques. Key exclusion criteria 
included a history of dysphagia, dysphagia from a condition other than 
stroke, advanced dementia, implanted pacemaker or cardiac defibrilla-
tor in situ, unstable cardiopulmonary status or a condition that compro-
mised cardiac or respiratory status, distorted oropharyngeal anatomy, 
additional diagnosis of a progressive neurological disorder, receiving 
continuous oxygen treatment, or pregnant or nursing mother.
Ethics and Approvals
The study was approved by national ethics committees and competent 
authorities in each participating country, and locally at each site, and 
was adopted by the UK National Institute for Health Research Stroke 
Research Network. We obtained written informed consent from 
each patient, or proxy consent from a relative when the patient did 
not have capacity (eg, because of dysphasia and confusion), before 
enrollment and in accordance with national regulations; in Germany, 
the Bundesamt für Strahlenschutz regulatory authority did not allow 
proxy consent. The trial was run by a Trial Management Committee 
(P.M.B., S.H., C.M., and J.L.). An independent data-monitoring 
committee reviewed unmasked data every 6 months. The trial was 
registered as ISRCTN25681641.
Randomization
VFS (see below) was performed as a study procedure after consent to 
confirm the presence of dysphagia (PAS ≥3).14 Investigators entered 
baseline and follow-up data into a commercial database (Rave, 
Medidata Solutions, Inc) linked to a randomization list (Quantics 
Consulting, Ltd). The data were checked to confirm the patient’s 
eligibility, and the system then assigned a participant to treatment 
with active PES or sham PES with allocation 1:1. Allocation was by 
randomly permuted blocks (of size 6) with stratification by center 
and feeding status (presence/absence of artificial feeding) to enhance 
balance between treatment groups.
VFS
VFS was performed using local protocols at each participating site by 
a speech and language therapist or a radiologist. At each time point 
(baseline and weeks 2 and 12), each participant was given up to 6×5 
mL bolus drinks of contrast agent (Omnipaque 300 in UK, Visipaque 
270 in France, or Accupaque 300) of liquid consistency (≈40% wt/
vol). A 50 mL drink of contrast agent was then administered and 
swallows recorded.
At baseline, bolus drinks were taken until 3 were positive (ie, 
at least 1 swallow within a bolus of PAS ≥3); once achieved, fur-
ther bolus drinks were not given to reduce the risk of aspiration 
and pneumonia. Hence, between 3 and 7 boli (each inducing ≥1 
swallows) were administered. Once completed, quality-assured 
digital VFS image files for each swallow for each bolus were sent 
immediately to 1 of 2 independent adjudicators who were blinded 
to clinical information and who confirmed whether the patient ful-
filled the inclusion criteria on the basis of aspiration of radiological 
contrast. Use of digital VFS reduced the risk of image degradation 
on file transfer. Once confirmation was received, treatment could 
be started. VFS images at weeks 2 and 12 were similarly uploaded 
and assessed by 1 of 2 adjudicators who were blinded to patient 
details and randomization. Silent aspiration was defined as aspira-
tion without an attempted cough as seen on the video file, accom-
panying sound, or event monitor.
Procedures
Sterile single-patient use treatment catheters (Phagenyx, Phagenesis, 
Ltd, Manchester, UK), which contain an inner lumen for feeding, 
were inserted via the nose by trained staff. The catheter was inserted 
to an aboral depth related to the patient’s height so that the pair of ring 
treatment electrodes located on the outer surface of the catheter were 
adjacent to the pharynx.
Treatment was started once dysphagia was confirmed by VFS and 
given daily for 3 days.9 At each session, the catheter was connected to 
the controlling base station, and electric current at 5 Hz was increased 
incrementally from 1 mA to detect threshold (patient first aware 
of stimulation) and then tolerated (patient does not want current 
increased further) intensity levels in all patients. Those randomized 
to active PES were then administered this for 10 minutes at a treat-
ment current (mA) of threshold plus 75% of the difference between 
threshold and tolerance levels; this paradigm was used successfully 
in earlier studies of PES and considered to be an effective level of 
stimulation without being too near the tolerance level.12 Patients ran-
domized to sham therapy had no stimulation after establishment of 
threshold and tolerated levels. Patients, but not the treating researcher, 
were masked to treatment assignment. Treatment could be stopped if 
the patient withdrew consent, for safety reasons, or if unacceptable 
adverse events developed.
Active or sham PES treatment was given in addition to standard 
stroke care, including thrombolysis if administered at admission 
to hospital, and rehabilitation. Systematic use of antihypertensive 
agents (all patients), oral antithrombotic and lipid-lowering agents, 
and carotid endarterectomy (patients with ischemic stroke) were 
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recommended for secondary prevention as per each site’s local prac-
tice. The final diagnosis was confirmed at discharge based on clinical 
presentation and neuroimaging.
Outcomes
The primary outcome measure was radiological aspiration at 2 weeks 
assessed as the PAS using VFS.14 The timing of VFS at 2 weeks 
reflected that used in 3 pilot trials.12 As a secondary outcome, PAS 
was also measured at 12 weeks.
Other prespecified secondary outcomes at 2, 6, and 12 weeks included 
clinical dysphagia (DSRS9; see the online-only Data Supplement), 
dependency (modified Rankin Scale [mRS]15,16), activities of daily liv-
ing/disability (Barthel Index17), impairment (NIHSS18), health-related 
quality of life (European Quality of Life-5 Dimensions [EQ-5D],19 from 
which health utility status was calculated [EQ-5D-HUS]), and nutri-
tional measures (weight, mid-arm circumference, and blood albu-
min). At discharge from initial admittance to hospital, investigators 
recorded duration of stay and discharge destination (to institution or 
home).
The safety outcomes were all-cause case fatality and cause-spe-
cific case fatality; serious adverse events and serious adverse device-
related events; and cases of chest infection or pneumonia (diagnosed 
locally because the diagnosis of chest infection and pneumonia is 
poorly defined20).
A member of the central research team (S.H.), who was masked to 
treatment assignment, validated and categorized investigator-reported 
serious adverse events, including cause-specific deaths. Patients who 
did not receive their assigned treatment or who did not adhere to the 
protocol were followed up in full. The recruiting site, using a separate 
nontreating researcher who was masked to treatment allocation, did 
post-treatment follow-ups at 2, 6, and 12 weeks.
Statistical Analyses
The statistical analysis plan was published on the Phagenesis, Ltd, 
website before data lock and unblinding: http://www.phagenesis.
com/wp-content/uploads/2012/09/Statistical-Analysis-Plan-STEPS.
pdf (March 21, 2012). The trial was designed to recruit 140 patients 
so as to detect an absolute reduction in the change in PAS (mean 
of all swallows from all available boli) from baseline to 2 weeks of 
1.1 point (SD 1.8) between the treatment groups, with power 90%, 
2-sided significance 5%, and allowance for incomplete data/losses to 
follow-up in 15% of patients. After analysis of individual patient data 
from 3 pilot studies,12 the primary analysis was changed to compari-
son between the treatment groups of the mean of the worst swallow 
in each of the 3 to 7 available boli (with adjustment for the same at 
baseline, and no imputation of missing data) because this seemed to 
be more robust statistically and was felt to be clinically more relevant, 
a decision that was made before unblinding of data.
Four analysis populations were created: randomized, all those 
who were assigned to PES or sham treatment; safety, all randomized 
patients who had treatment attempted, that is, insertion of the treat-
ment catheter with or without PES/sham; efficacy, all randomized 
patients who received at least 1 episode of PES/sham treatment and 
who had the primary outcome (PAS) measured at both baseline and 
2 weeks; and per protocol, randomized patients who received all 3 
treatments and who had PAS data measured at baseline and 2 weeks.
Swallowing was analyzed as a comparison between the treatment 
groups using multiple linear regression with adjustment of the on-
treatment PAS for baseline PAS, stratification variables (site and feed-
ing status), and prognostic baseline variables (age, sex, and NIHSS). 
Secondary analyses used multiple linear regression (continuous data, 
eg, EQ-5D), ordinal logistic regression (ordered categorical data, eg, 
mRS), binary logistic regression (dichotomous data, eg, PAS ≤3, seri-
ous adverse events, and chest infection), and Kaplan–Meier and Cox 
regression models (time to event, eg, death). 95% confidence inter-
vals (CI) are presented, and P<0.05 was considered statistically sig-
nificant. Analyses were performed using SAS version 9.3. Summary 
meta-analyses based on group data from Swallowing Treatment 
Using Pharyngeal Electrical Stimulation (STEPS) and earlier trials9,11 
were produced using the Cochrane Collaboration’s Review Manager 
software (version 5.3).
Additional Information
Further information on Materials and Methods is given in the online-
only Data Supplement.
Results
Between April 2012 and September 2014, we consented 195 
patients; screened 181 patients with VFS; assigned treatment 
in 162 patients (randomized population); attempted treatment 
in 152 patients (safety population); treated (with at least 1 
session of PES or sham) 141 patients; and obtained VFS in 
126 patients at 2 weeks (primary outcome population) and 
95 patients at 12 weeks (Figure 1). The reduction in numbers 
between consent and randomization reflected patients who: 
screened negative for aspiration on VFS, could not have the 
catheter inserted, and did not have a VFS 2 weeks after treat-
ment. The 162 randomized patients were recruited from 20 
sites in 5 countries (Denmark, France, Germany, Spain, and 
United Kingdom, listed in the online-only Data Supplement); 
of these, 87 patients were assigned active PES and 75 patients 
were assigned to the sham group (Figure 1). Hundred and one 
patients (62.3%) were recruited from the United Kingdom. 
The randomized groups were well balanced at baseline (Table 
1): mean age 74 (SD 11) years, 94 (58%) were male, and 
143 (89%) patients had an ischemic stroke. The mean time 
from stroke to randomization was 13 (10) days. The Data 
Monitoring Committee reviewed the trial on 3 occasions and 
recommended that the trial should continue each time.
Adherence with assignment to active or sham PES was 
good in 141 participants who received at least 1 treatment 
session. There were no material differences at baseline in 15 
treated participants who did not have VFS at 2 weeks versus 
126 treated participants who did have VFS. No patients ran-
domized to sham received active treatment, and all patients 
with a catheter inserted and randomized to PES received at 
least 1 active treatment session. The mean treatment stimu-
lation level was 14.5 mA in those randomized to PES, with 
mean treatment duration 9.8 minutes and mean number of 
treatments 3.0 (Table I in the online-only Data Supplement). 
However, evidence of suboptimal treatment current levels 
seemed to be present: 58% of PES-treated patients had a treat-
ment level <10.2 mA (a figure chosen from earlier research12), 
identical treatment and threshold levels, or a treatment level 
less than threshold.
In the primary outcome population, the mean PAS at base-
line was 4.8 (SD 2.0) and reduced in both active PES and 
sham PES groups at 2 weeks (Table 2). When adjusted for site, 
age, NIHSS, baseline feeding status, and PAS, there was no 
difference in PAS at 2 weeks, mean difference 0.14 (95% CI, 
−0.37 to 0.64; P=0.60; Table 2 and Figure 2); the mean change 
in PAS from baseline to 2 weeks did not differ between the 
2 treatment groups: active PES −1.2 (1.8) versus sham PES 
−1.2 (1.8) and difference 0.14 (−0.37 to 0.64). Meta-analysis 
of individual patient data from earlier studies suggested that 
different approaches to statistical analysis varied in their sta-
tistical efficiency;12 in sensitivity analyses, PAS did not differ 
between the groups when assessed using different statistical 
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approaches (Table II in the online-only Data Supplement). 
When assessed in prespecified subgroups, no significant inter-
actions were present (Figure 2).
PES had no significant effects on secondary measures of 
swallowing and feeding, including radiological aspiration 
(PAS) at 12 weeks, and clinical dysphagia (DSRS) and feed-
ing route at weeks 2 and 12 (Table 3; Table II in the online-
only Data Supplement). Apparent tendencies in favor of PES 
were present at week 2 (but not at week 12) for functional 
measures of outcome (mRS and Barthel Index). Other mea-
sures did not differ between the treatment groups (Table 3; 
Table II in the online-only Data Supplement). When assessed 
in prespecified subgroups, significant interactions were 
present between clinical dysphagia (DSRS) and treatment 
assignment for age and PAS (Figure I in the online-only Data 
Supplement). The number of patients with chest infection or 
pneumonia occurring after randomization (and so possibly 
related to VFS rather than subsequent PES/sham treatment) 
did not differ between the treatment groups: PES 21, sham 
11 (P=0.19). The overall rate of serious adverse events occur-
ring by end of follow-up did not differ between the 2 groups, 
and no serious adverse device-related events occurred in 
either group (Table III in the online-only Data Supplement). 
The cumulative risk of all-cause death during follow-up did 
not differ between the group given PES and the sham treat-
ment (Figure II in the online-only Data Supplement). The 
Figure 1. Flow of patients through the trial: consented, 195; screened with VFS, 181; randomized, 162; treatment attempted, 152; treated, 
141; treated with VFS at 2 weeks, 126; all 3 treatments received with VFS at 2 weeks, 123; treated with VFS at 12 weeks, 95. AE indicates 
adverse event; CIP, clinical investigational plan; Rx, randomization; SLT, speech and language therapy; and VFS, videofluoroscopy. 
1566  Stroke  June 2016
Table 1. Baseline Characteristics in the Randomized Population by Treatment Assignment
N Randomized PES Sham
Patients 162 162 87 75
Age, y 162 74.4 (11.2) 74.0 (9.9) 74.9 (12.6)
Sex, male (%) 162 94 (58.0) 48 (55.2) 46 (61.3)
Race/ethnicity (%) 162
  Asian 15 (9.3) 9 (10.3) 6 (8.0)
  Black 4 (2.5) 0 (0.0) 4 (5.3)
  White 139 (85.8) 74 (85.1) 65 (86.7)
  Other 4 (2.5) 4 (4.6) …
Modified Rankin Scale (/6) 153 4.0 (1.1) 3.9 (1.1) 4.1 (1.2)
Barthel Index (/100) 153 28.4 (29.8) 32.4 (31.7) 23.8 (26.8)
Stroke, previous (%) 162 23 (14.2) 15 (17.2) 8 (10.7)
Visible on imaging (%) 161 42 (26.1) 25 (28.7) 17 (23.0)
Stroke type (%) 161
  Ischemic/normal 143 (88.8) 77 (89.5) 66 (88.0)
  Intracerebral hemorrhage 17 (10.6) 9 (10.5) 8 (10.7)
  Nonstroke 1 (0.6) 0 (0) 1 (1.3)
Side of CT lesion (%) 158
  Left 63 (39.9) 33 (38.4) 30 (41.7)
  Right 69 (43.7) 36 (41.9) 33 (45.8)
  No lesion 26 (16.5) 17 (19.8) 9 (12.5)
Syndrome (%) 157
  Total anterior circulation 41 (26.1) 21 (24.4) 20 (28.2)
  Partial anterior circulation 69 (43.9) 44 (51.2) 25 (35.2)
  Lacunar 46 (29.3) 21 (24.4) 25 (35.2)
  Posterior circulation 1 (0.6) 0 (0.0) 1 (1.4)
Severity, NIHSS (/42) 152 9.9 (6.4) 9.6 (6.5) 10.2 (6.2)
Dysphasia, NIHSS (%) 152 55 (36.2) 29 (35.8) 26 (36.6)
Onset to randomization (days) 162
  Mean (SD) 13.4 (9.7) 12.6 (9.5) 14.4 (10.0)
  Median (IQR) 11 (6–18) 10 (5–17) 12 (6–21)
DSRS (/12) 154 7.6 (3.8) 8.0 (3.9) 7.0 (3.5)
TOR-BSST, failed (%) 162 158 (97.5) 85 (97.7) 73 (97.3)
Feeding route (%) 162
  Oral, normal diet 10 (6.2) 5 (5.7) 5 (6.7)
  Oral, soft diet 45 (27.8) 23 (26.4) 22 (29.3)
  Nasogastric 90 (55.6) 52 (59.8) 38 (50.7)
  PEG 4 (2.5) 3 (3.4) 1 (1.3)
  Other 13 (8.0) 4 (4.6) 9 (12.0)
Weight (kg) 153 71.9 (16.4) 71.9 (15.3) 72.0 (17.6)
Body mass index (kg/m2) 148 25.2 (5.0) 25.7 (4.8) 24.7 (5.2)
Mid-arm circumference (cm) 143 28.3 (3.6) 28.2 (3.7) 28.5 (3.6)
Albumin (g/L) 144 36 (5.7) 36.4 (5.8) 35.5 (5.6)
Chest infection (%) 156 8 (5.1) 3 (3.6) 5 (6.9)
Penetration aspiration scale (/8) 162 4.7 (2.0) 4.7 (2.1) 4.7 (1.9)
  PAS >2 162 148 (91.4) 79 (90.8) 69 (92.0)
Data are number (%), median (interquartile range), or mean (SD). CT indicates computed tomography; DSRS, dysphagia 
severity rating scale; NIHSS, National Institutes of Health Stroke Scale; PAS, penetration aspiration score; PEG, percutaneous 
endoscopic gastrostomy; and TOR-BSST, Toronto Bedside Swallowing Screening Test.
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treatment equipment was rated as easy to use by investiga-
tors who operated the PES treating device; however, passing 
the catheter was rated as difficult in one third of investigators 
(Table IV in the online-only Data Supplement).
In a summary meta-analysis of results from STEPS and 
earlier trials,9,11 there was no difference in PAS between 
patients randomized to PES versus sham (Figure III in the 
online-only Data Supplement). In contrast, PES was associ-
ated with a larger reduction (ie, improvement) in DSRS than 
patients randomized to sham, mean difference −0.94 (95% CI, 
−1.85 to −0.03; P=0.04; Figure IV in the online-only Data 
Supplement).
Discussion
In patients with dysphagia post stroke, PES had no signifi-
cant effect on radiological aspiration or clinical dysphagia, 
assessed as PAS and dysphagia severity rating scale, respec-
tively. Similarly, PES had no effect on dependency (mRS), 
disability (Barthel Index), or impairment (NIHSS). No safety 
issues were identified.
The explanation for these largely neutral results remains 
unclear but many possibilities need to be examined. First, PES 
may simply not be effective for treating dysphagia after stroke; 
however, this seems unlikely in the context of a positive indi-
vidual patient data meta-analysis of earlier poststroke PES stud-
ies,9,11,12 the positive summary meta-analysis for DSRS presented 
here, and positive trials in multiple sclerosis and stroke patients 
with a tracheostomy.21,22 Second, the severity of dysphagia at 
baseline will itself determine the likely success of treatment. 
Across the field of acute stroke, it is challenging to demonstrate 
efficacy in a group of patients with mild impairment because 
many patients will regain normal function spontaneously; in 
this context, mild dysphagia is likely to resolve spontaneously. 
Importantly, the regulatory authority in 1 country (Germany) 
limited recruitment to patients who could provide consent for 
themselves, and this resulted in inclusion of patients with only 
milder stroke and aspiration, a decision that would challenge 
demonstrating efficacy for many interventions. Although the 
mean baseline PAS in STEPS (PAS=4.8) was similar to previ-
ous stroke trials of PES (4.312; Table V in the online-only Data 
Supplement), it was lower than in a positive trial in multiple 
sclerosis (PAS=6.521). Of relevance, patients randomized to 
sham in the earlier studies tended to have minimal or no over-
all improvement in PAS or DSRS, whereas sham patients in 
STEPS showed improvement (Table V in the online-only Data 
Supplement). Confounding this point is the potential relevance 
of VFS to the diagnosis of dysphagia and its severity; in particu-
lar, PAS scores were noted to be highly variable during admin-
istration of contrast boli. Additionally, VFS was not readily 
available at many sites thereby limiting recruitment. We chose 
PAS (using thin boli) as a primary outcome measure based on 
previous pilot studies which showed a significant improvement 
in this measure in the active PES arm8,9 but recognize that PAS 
alone does not capture information about swallowing efficiency 
and bolus control as might come from using thick liquid boli 
and measures of pharyngeal residue/timings.
Third, and related to the issue of severity and spontaneous 
resolution, patients who are enrolled early after stroke will 
comprise a mixed group of those with severe dysphagia and 
those with milder dysphagia that will improve without treat-
ment. However, later recruitment will enhance the propor-
tion of patients with severe (or fixed) dysphagia. In reality, 
STEPS and earlier trials each recruited patients at ≈2 weeks 
poststroke.12 Fourth, participants received variable amounts of 
active speech and language therapy, and this may have con-
founded the effect of additive PES.
Fifth, patients randomized to PES may have received sub-
therapeutic stimulation levels because mean levels were lower 
in STEPS (mean treatment 14.8 mA) than in previous positive 
Table 2. PAS at 2 Weeks in the Efficacy Population by Treatment Assignment
All (N=126) PES (N=70) Sham (N=56)
OR/MD  
(95% CI), Adjusted P Value
OR/MD  
(95% CI), Unadjusted P Value
Baseline
  PAS (/8) 4.8 (2.0) 4.8 (2.1) 4.7 (1.9) … … … …
2 wk primary outcome
  Mean of all boli (/8) 3.6 (2.0) 3.7 (2.0) 3.6 (1.9) 0.14 (−0.37 to 0.64) 0.60 0.06 (−0.62 to 0.74) 0.86
  Change from baseline −1.2 (1.8) −1.2 (1.8) −1.2 (1.8) 0.14 (−0.37 to 0.64) 0.60 0.00 (−0.62 to 0.61) 1.00
  Any PAS >3 (%) 105 (83.3) 60 (85.7) 45 (80.4) 1.22 (0.29 to 5.15) 0.79 1.47 (0.57 to 3.75) 0.42
12 wk
  Mean of all boli (/8) 3.2 (2.1) 3.3 (2.2) 3.0 (2.1) 0.29 (−0.04 to 0.99) 0.41 0.24 (−0.6 to 1.08) 0.57
  Any PAS >3 (%) 69 (72.6) 36 (70.6) 33 (75.0) 0.62 (0.20 to 1.90) 0.41 0.80 (0.32 to 1.99) 0.63
Repeated measures
  Mean (/8)* … 4.1 (2.3) 3.9 (2.3) 0.51 (−0.23 to 1.25) 0.18 0.19 (−0.67 to 1.04) 0.67
All patients had diagnostic videofluoroscopy at both baseline and 2 weeks and received at least 1 treatment session. Data are number (%), median (interquartile 
range), or mean (SD), with comparisons using unadjusted and adjusted multiple linear, ordinal logistic, or binary logistic regression. CI indicates confidence interval; MD, 
mean difference; OR, odds ratio; PAS, penetration aspiration score; and PES, pharyngeal electric stimulation.
*Includes death: PAS=9.
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trials in stroke (16.8 mA12). Using a treatment level of <10.2 
mA (mean − 1 SD in previous trials12) or treatment threshold 
level ≤0 mA, 58% of participants randomized to PES may have 
been undertreated. Importantly, the magnitude of stimulation 
has been shown previously to be associated with improvement 
in aspiration.8 Investigator concerns about the potential to 
harm patients seem to have explained this situation, although 
the study showed no evidence of harm, and PES may be deliv-
ered safely up to 50 mA (the maximum that can be delivered 
by the base station), as shown in another study in patients with 
stroke.22 And last, assessment of threshold and tolerance levels 
in patients randomized to sham PES may have amounted to an 
element of stimulation. For example, a participant randomized 
to sham but who had high threshold and tolerance currents 
Figure 2. Effect of treatment on penetration aspiration score in prespecified subgroups determined at baseline, with analysis using 
adjusted multiple linear regression. CL indicates confidence limit; DSRS, dysphagia severity rating scale; LACS, lacunar circulation syn-
drome; MD, mean difference; NIHSS, National Institutes of Health Stroke Scale; PACS, partial anterior circulation syndrome; PAS, pen-
etration aspiration score; PES, pharyngeal electric stimulation; and TACS, total anterior circulation syndrome.
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will have received a potentially therapeutic form of stimula-
tion for 10 to 20 minutes (as compared with the 30+ minutes 
that patients randomized to active treatment receive). These 
potential explanations for the STEPS results have implications 
for the design of future trials of PES (and, indeed, other device 
trials) and training of investigators.
STEPS has several strengths, including the large sample size 
relative to previous studies of PES; generalizability because of 
wide inclusion criteria with both ischemic and hemorrhagic 
stroke, cortical, lacunar, and posterior syndromes, and a wide 
time window; recruitment from multiple countries in Europe; 
central concealment of treatment assignment; prospective 
collection of multiple aspiration, dysphagia, functional, and 
safety outcomes; and quality care in stroke units.
However, several limitations are also present. First, 195 
patients were consented, 162 patients randomized but only 
126 received at least 1 treatment session and had both a base-
line and on-treatment PAS. Several factors explain this drop-
out, including withdrawal of consent and failure of insertion 
of the treatment catheter (Figure 1). A protocol amendment 
required that the treatment catheter had to be inserted before, 
and not after, randomization to reduce losses of patients who 
were randomized but could not be treated. Second, PES was 
delivered in 141 patients but 15 could not have VFS per-
formed at both baseline and week 2 thereby excluding them 
from the primary analysis. Third, PES was given in a single-
blind design with the patient but not treating person masked 
to stimulation. Some patients receiving active PES may have 
been aware of stimulation, whereas patients randomized to 
sham PES may have been aware of stimulation during thresh-
old testing and possibly noticed that this was absent during the 
treatment sessions. Nevertheless, clinical outcomes measured 
at 2, 6, and 12 weeks were assessed by trained staff who were 
masked to treatment assignment and who were not involved in 
hospital care of enrolled patients. Furthermore, VFS images 
were adjudicated by radiologists or speech therapists who 
were similarly masked to randomized group.
In conclusion, we found that PES did not reduce radiologi-
cal aspiration or clinical dysphagia. This result differs from a 
positive meta-analysis of previous small trials of PES in post-
stroke dysphagia12 and may result from several factors, includ-
ing enrollment of patients with mild dysphagia, potential 
undertreatment with PES, and possible active stimulation of 
control patients. In view of this discrepancy, and the potential 
risk of overestimating treatment effect from smaller studies, 
further studies are planned in stroke patients with severe dys-
phagia or those requiring intensive care including ventilation.
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Table 3. Clinical and Safety Outcomes by Treatment Assignment in Patients Who Received At Least 1 Active or Sham Treatment 
and Who Had Outcome Measured
N All PES Sham OR/HR/MD
P Value 
Adjusted OR/HR/MD
P Value 
Adjusted
2 wk
  DSRS (/12)* 133 5.1 (3.8) 5.2 (4.1) 4.9 (3.6) 0.31 (−0.56 to 1.18) 0.49 0.23 (−1.07 to 1.54) 0.72
  NIHSS (/42)* 134 9.6 (7.2) 9.0 (7.4) 10.2 (7.1) −0.05 (−1.42 to 1.32) 0.94 −1.19 (−3.64 to 1.26) 0.34
  mRS (/6)* 134 3.9 (1.1) 3.7 (1.2) 4.1 (1.0) 0.53 (0.23 to 1.22) 0.14 0.49 (0.26 to 0.92) 0.028
  BI (/100)* 134 36.2 (34.9) 41.3 (37.2) 29.8 (31.0) 1.57 (−3.60 to 6.73) 0.55 11.45 (−0.22 to 23.13) 0.055
  Death (%) 141 2 (1.4) 1 (1.3) 1 (1.6) … … 0.81 (0.05 to 13.13) 0.88
12 wk
  DSRS (/12)* 124 4.2 (5.1) 4.4 (5.2) 3.9 (5.1) 1.01 (−0.44 to 2.46) 0.17 0.58 (−1.23 to 2.39) 0.53
  EQ-5D as HUS (/1)* 113 0.02 (0.40) 0.08 (0.41) −0.04 (0.39) 0.13 (0.00 to 0.27) 0.054 0.12 (−0.03 to 0.27) 0.11
  EQ-VAS* 105 50.3 (30.7) 51.6 (30.1) 48.6 (31.7) −4.17 (−15.22 to 6.88) 0.46 3.03 (−8.70 to 14.76) 0.61
Disposition (%) 141 0.66 (0.30 to 1.49) 0.32 0.63 (0.31 to 1.26) 0.19
  Home 30 (21.3) 20 (25.6) 10 (15.9) … … … …
  Institution 93 (66.0) 49 (62.8) 44 (69.8) … … … …
  Died 18 (12.8) 9 (11.5) 9 (14.3) … … … …
Time to event
  Discharge (days) 141 28.2 (22.8) 27.7 (22.7) 28.7 (23.0) −0.33 (−7.79 to 7.12) 0.93 −0.97 (−9.72 to 7.78) 0.83
  Death (%) 141 18 (12.8) 9 (11.5) 9 (14.3) 1.11 (0.34 to 3.59) 0.86 0.79 (0.32 to 2.00) 0.62
BI indicates Barthel Index; DSRS, dysphagia severity rating scale; EQ-5D, European Quality of Life-5 Dimensions; EQ-VAS, European Quality of Life Visual Analogue 
Scale; HR, hazard ratio; HUS, health utility status; MD, mean difference; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; 
and PES, pharyngeal electric stimulation.
*Includes death: NIHSS=43, DSRS=13, mRS=6, BI=−5, and HUS=0.
1570  Stroke  June 2016
Sources of Funding
The trial was sponsored and funded by Phagenesis, Ltd (Manchester, 
UK).
Disclosures
P.M. Bath received honoraria for work as the Chief Investigator and 
for consultancy. S. Hamdy is the inventor of PES and has stock in 
Phagenesis. J. Love was an employee of Phagenesis. Institutions 
using P. M. Bath, D. Cohen, H.K. Iversen, R. Dziewas, V. Woisard, 
and P. Clavé received per-patient fees for recruitment. P.M. Bath, P. 
Scutt, D. Cohen, H.K. Iversen, R. Dziewas, and V. Woisard received 
travel expenses for attending meetings. The other authors report no 
conflicts.
References
 1. Smithard DG, Smeeton NC, Wolfe CD. Long-term outcome after stroke: 
does dysphagia matter? Age Ageing. 2007;36:90–94. doi: 10.1093/
ageing/afl149.
 2. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell 
R. Dysphagia after stroke: incidence, diagnosis, and pulmonary 
complications. Stroke. 2005;36:2756–2763. doi: 10.1161/01.STR. 
0000190056.76543.eb.
 3. Falsetti P, Acciai C, Palilla R, Bosi M, Carpinteri F, Zingarelli A, 
et al. Oropharyngeal dysphagia after stroke: incidence, diagnosis, 
and clinical predictors in patients admitted to a neurorehabilitation 
unit. J Stroke Cerebrovasc Dis. 2009;18:329–335. doi: 10.1016/j.
jstrokecerebrovasdis.2009.01.009.
 4. Geeganage C, Beavan J, Ellender S, Bath PM. Interventions for dysphagia 
and nutritional support in acute and subacute stroke. Cochrane Database 
Syst Rev. 2012;10:CD000323. doi: 10.1002/14651858.CD000323.pub2.
 5. Hamdy S, Aziz Q, Rothwell JC, Singh KD, Barlow J, Hughes DG, et al. 
The cortical topography of human swallowing musculature in health and 
disease. Nat Med. 1996;2:1217–1224.
 6. Hamdy S, Rothwell JC, Aziz Q, Singh KD, Thompson DG. Long-term 
reorganization of human motor cortex driven by short-term sensory stim-
ulation. Nat Neurosci. 1998;1:64–68. doi: 10.1038/264.
 7. Hamdy S, Aziz Q, Rothwell JC, Crone R, Hughes D, Tallis RC, et al. 
Explaining oropharyngeal dysphagia after unilateral hemispheric stroke. 
Lancet. 1997;350:686–692. doi: 10.1016/S0140-6736(97)02068-0.
 8. Fraser C, Power M, Hamdy S, Rothwell J, Hobday D, Hollander I, 
et al. Driving plasticity in human adult motor cortex is associ-
ated with improved motor function after brain injury. Neuron. 
2002;34:831–840.
 9. Jayasekeran V, Singh S, Tyrrell P, Michou E, Jefferson S, Mistry S, et 
al. Adjunctive functional pharyngeal electrical stimulation reverses swal-
lowing disability after brain lesions. Gastroenterology. 2010;138:1737–
1746. doi: 10.1053/j.gastro.2010.01.052.
 10. Jefferson S, Mistry S, Michou E, Singh S, Rothwell JC, Hamdy S. 
Reversal of a virtual lesion in human pharyngeal motor cortex by 
high frequency contralesional brain stimulation. Gastroenterology. 
2009;137:841–849, 849.e1. doi: 10.1053/j.gastro.2009.04.056.
 11. Vasant D, Michou E, Tyrrell P, Jayasekeran V, Mistry S, O’Leary N, et al. 
Oc-063 pharyngeal electrical stimulation (pes) in dysphagia post-acute 
stroke: a double blind, randomised trial. Gut. 2014;63:A31.
 12. Scutt P, Lee HS, Hamdy S, Bath PM. Pharyngeal electrical stimulation 
for treatment of poststroke dysphagia: individual patient data meta-analy-
sis of randomised controlled trials. Stroke Res Treat. 2015;2015:429053. 
doi: 10.1155/2015/429053.
 13. Dziewas R, Warnecke T, Olenberg S, Teismann I, Zimmermann J, 
Kramer C, et al. Towards a basic endoscopic assessment of swallowing in 
acute stroke - development and evaluation of a simple dysphagia score. 
Cerebrovasc Dis. 2008;26:41–47. doi: 10.1159/000135652.
 14. Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetra-
tion-aspiration scale. Dysphagia. 1996;11:93–98.
 15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn 
J. Interobserver agreement for the assessment of handicap in stroke 
patients. Stroke. 1988;19:604–607.
 16. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, et 
al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-
controlled trial. Lancet. 2001;358:702–710.
 17. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md 
State Med J. 1965;14:61–65.
 18. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. 
Measurements of acute cerebral infarction: a clinical examination scale. 
Stroke. 1989;20:864–870.
 19. Brooks R. EuroQol: the current state of play. Health Policy. 
1996;37:53–72.
 20. Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, Di Napoli M, et 
al. How is pneumonia diagnosed in clinical stroke research? A system-
atic review and meta-analysis. Stroke. 2015;46:1202–1209. doi: 10.1161/
STROKEAHA.114.007843.
 21. Restivo DA, Casabona A, Centonze D, Marchese-Ragona R, Maimone 
D, Pavone A. Pharyngeal electrical stimulation for dysphagia associated 
with multiple sclerosis: a pilot study. Brain Stimul. 2013;6:418–423. doi: 
10.1016/j.brs.2012.09.001.
 22. Suntrup S, Marian T, Schröder JB, Suttrup I, Muhle P, Oelenberg S, et al. 
Electrical pharyngeal stimulation for dysphagia treatment in tracheoto-
mized stroke patients: a randomized controlled trial. Intensive Care Med. 
2015;41:1629–1637. doi: 10.1007/s00134-015-3897-8.
